Companies › Jaguar Gene Therapy
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JAG201 Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9 | SHANK3 | Phase 1 | SHANK3 Haploinsufficiency | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06662188 | JAG201 | Phase 1 | SHANK3 Haploinsufficiency | Other | Jun 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.